Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido

Autores:: Jiménez, Adriana
Carrero Forero, Germán

Tipo de recurso:: Article of journal

Fecha de publicación:: 2013

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_22e09e530b1991258a8fd66b7e5ef1a5
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2862
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
dc.title.translated.eng.fl_str_mv	Risk factors in extenoeo-spectrum betalactamase producing Escherichia coli ano Klebsiella pneumoniae infection and colonization
title	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
spellingShingle	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido factores de riesgo antibiótico resistencia betalactamasas de espectro extendido risk factors antibiotic resistance extended-spectrum betalactamases
title_short	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
title_full	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
title_fullStr	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
title_full_unstemmed	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
title_sort	Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido
dc.creator.fl_str_mv	Jiménez, Adriana Carrero Forero, Germán
dc.contributor.author.spa.fl_str_mv	Jiménez, Adriana Carrero Forero, Germán
dc.subject.spa.fl_str_mv	factores de riesgo antibiótico resistencia betalactamasas de espectro extendido
topic	factores de riesgo antibiótico resistencia betalactamasas de espectro extendido risk factors antibiotic resistance extended-spectrum betalactamases
dc.subject.eng.fl_str_mv	risk factors antibiotic resistance extended-spectrum betalactamases
publishDate	2013
dc.date.accessioned.none.fl_str_mv	2013-03-01 00:00:00 2022-06-29T19:37:16Z
dc.date.issued.none.fl_str_mv	2013-03-01
dc.date.available.none.fl_str_mv	2013-03-01 00:00:00 2022-06-29T19:37:16Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_dcae04bc
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ARTREV
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	10.31260/RepertMedCir.v22.n1.2013.843
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2862
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://doi.org/10.31260/RepertMedCir.v22.n1.2013.843
identifier_str_mv	10.31260/RepertMedCir.v22.n1.2013.843 0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2862 https://doi.org/10.31260/RepertMedCir.v22.n1.2013.843
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Villegas MV, Kallan JN, Quinteros MG, Casellas JM. Prevalence of extended spectrum beta-Iactamases in South America. Clin Microbio! lnfect. 2008;14 Suppl 1:154-8. 2. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta Iactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50: 1257-62. 3. Paterson DL, Bonomo RA. Extended-spectrum beta-Iactamases: a clinical up date. Clin Microbio! Rev. 2005; 18:657-86. 4. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Anti microb Agents Chemother. 20 I 0;54:969-76. 5. Gunseren F, Marnikoglu L, Ozturk S, et al. A surveillance study of antimicrobial resistance of gram-negative bacteria isolated frorn intensive care units in eighl hospitals in Turkey. J Antimicrob Chemother. 1999;43:373-8. 6. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese !CU Study Groups. JAMA. 1999;281:67-71. 7. Albertini MT, Benoit C, Berardi L, et al. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended spectrurn beta-Iaclamase (ESBLE) in Northem France: a five-year multicentre incidence study. J Hosp Infect. 2002;52: 107-13. 8. Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME, Jiang H. Broad-spectrum, transmissible beta-lactamases. N Engl J Med. I 988;319:723-4. 9. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS. Occu rrence of newer beta-lactamáses in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother. 2002;46:3837-42. 10. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002;30:458-75. 11. Bell JM, Tumidge JD, Gales AC, Pfaller MA, Jones RN, Sentry ASG. Preva lence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbio! Infect Dis. 2002;42:193-8. 12. Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN. ln vitro evaluation of ce fepime and other broad-spectrum beta-lactams in 22 medica! centers in Japan: a phase II tria! comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn Microbio! lnfect Dis. 1999;35:307-15. 13. Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC, Jones RN. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicro bial agents tested against over 2,000 clinical isolates from 22 medica] centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn Microbio) Infect Dis. 1999;34:123-34. 14. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and charac terization of isolates from Europe, the Americas, and the Western Pacific region. Clin lnfect Dis. 2001;32 Suppl 2:S94-103. 15. Mendes C, Hsiung A, Kiffer C, et al. Evaluation of the in vitro activity of 9 antimicrobials against bacteria! strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program. Braz J lnfect Dis. 2000;4:236-44. 16. Miranda MC, Perez F, Zuluaga T, et al. [Antimicrobial resistance in gram nega tive bacteria isolated from intensive care units of Colombian hospitals, WHO NET 2003, 2004 and 2005]. Biomedica. 2006;26:424-33. 17. Otman J, Cavassin ED, Perugini ME, Vidotto MC. An outbreak of extended spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unir in Brazil. lnfect Control Hosp Epidemiol. United States; 2002:8-9. 18. Pfaller MA, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resis tance Study Group. Diagn Microbiol lnfect Dis.1999;35:153-8. 19. Sader HS, Jones RN, Gales AC, et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medica! centers with a diag nosis of pneurnonia: analysis of results from the SENTRY Antimicrobial Surveil lance Program (] 997). SENTRY Latin America Study Group. Diagn Microbio! Infect Dis. 1998;32:289-301. 20. Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, Group SS. Preva lence of antimicrobial resistance among respiratory tract isolates in Latin Amer ica: results from SENTRY antimicrobialsurveillance program (1997-98). Braz J Infect Dis. 2000;4:245-54. 21. Villegas MV, Correa A, Perez F, et al. Prevalence and characterization of ex tended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn Microbiol lnfect Dis. 2004;49:217-22. 22. Espinal P, Garza-Ramos U, Reyna F, et al. ldentification of SHV-type and CTX M-12 extended-spectrum beta-lactamases (ESBLs) in multiresistant Enterobac teriaceae from Colombian Caribbean hospitals. J Chemother. 2010;22:160-4. 23. Tumbarello M, Spanu T, Sanguinetti M, et al. llloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Che mother. 2006;50:498-504. 24. Superti SV, Augusti G, Zavascki AP. Risk factors for and mortality of exten ded-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escheri chia coli nosocornial bloodstream infections. Rev Inst Med Trop Sao Paulo. 2009;51:211-6. 25. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp lnfect. 2008;68:108-15. 26. Chenoweth CE, Saint S. Urinary tract infections. Infect Dis Clin North Am. 2011;25:103-15. 27. Saint S, Chenoweth CE. Biofilms and catheter-associated urinary tract infections. Infect Dis Clin North Am. 2003;17:411-32. 28. Warren JW, Darnron D, Tenney JH, Hoopes JM, Deforge B, Muncie HL, Jr. Fever, bacteremia, and death as complications of bacteriuria in women with long term urethral catheters. J Infect Dis. 1987;155:l 151-8. 29. Classen DC, Larsen RA, Burke JP, Stevens LE. Prevention of catheter associated bacteriuria: clinical tria] of methods to block three known pathways of infection. Am J lnfect Control. 1991;19:136-42. 30. Garibaldi RA, Burke JP, Britt MR, Miller MA, Smith CB. Meatal colonization and catheter-associated bacteriuria. N Engl J Med. l 980;303:316-8. 31. Hartstein Al, Garber SB, Ward TI, Jones SR, Morthland VH. Nosocomial uri nary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control. 1981;2:380-6. 32. Kunin CM, McCormack RC. Prevention of catheter-induced urinary-tract infec tions by sterile closed drainage. N Engl J Med. 1966;274:1155-61. 33. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary traer infection in adults: 2009 Internatio nal Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin lnfect Dis. 2010;50:625-63. 34. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg lnfect Dis. 2001;7:342-7. 35. Huth TS, Burke JP, Larsen RA, Classen DC, Stevens LE. Randomized tria! of meatal care with silver sulfadiazine cream for the prevention of catheter-associa ted bacteriuria. J Infect Dis. 1992;165:14-8. 36. Platt R, Polk BF, Murdock B, Rosner B. Risk factors for nosocomial urinary tract infection. Arn J Epidemiol. 1986;124:977-85. 37. Anderson DJ, Kirkland KB, Kaye KS, et al. Underresourced hospital infection control and prevention programs: penny wise, pound foolish? Infect Control Hosp Epidemiol. 2007;28:767-73. 38. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infec tions: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol. 1996;17:552-7. 39. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control. 2005;33:501-9. 40. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Net work (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control. 2008;36:609-26. 41. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgerson RB. An attachable silver-impregnated cuff for prevention of infection with cen_tral venous catheters: a prospective randomized multicenter trial. Am J Med. 1988:85:307-14. 42. Weber DJ, Rutala WA. Central line-associated bloodstream infections: preven tion and management. lnfect Dis Clin North Am. 2011;25:77-102. 43. Baker AM, Meredith JW, Haponik EF. Pneumonia in intubated trauma patients. Microbiology and outcomes. Am J Respir Crit Care Med. 1996;153:343-9. 44. Craig CP, Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Jnfect Control. 1984;12:233-8. 45. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA. Risk factors for nosocomial pneumonia: comparing adult critical-care popula tions. Am J Respir Crit Care Med. 1996;153:158-62. 46. Jourdain B, Novara A, Joly-Guillou ML, et al. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med. 1995;152:241-6. 47. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ven tilator-associated pneumonia among intensive care unit patients in a suburban medica) center. Crit Care Med.2003;31:1312-7. 48. Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL. Nosocomial pneumónia in Medicare patients. Hospital costs and reimbursement pattems under the prospec tive payment system. Arcb Jntern Med. 1991;151:1109-14. 49. van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ. Oral decontamination is cost-saving in the prevention of ventilator associated pneumonia in intensive care units. Crit Care Med. 2004;32:126-30. 50. Cook DJ, Walter SO, Cook RJ, et al. lncidence of and risk factors far ventilator associated pneumonia in critically ill patients. Ann Intem Med. l998;129:433- 40. 51. Stonecypher K. Yentilator-associated pneumonia: the importance of oral care in intubated adults. Crit Care Nurs Q. 2010;33:339-47. 52. Cmich CJ, Safdar N, Maki DG. The role of the intensive care unit environment in the pathogenesis and prevention of ventilator-associated pneumonia. Respir Care. 2005;50:813-36; discussion 36-8. 53. O'Keefe-McCarthy S.Evidence-based nursing strategies to prevenl ventilator acquired pneumonia. Dynamics. 2006;17:8-l l. 54. Safdar N, Cmich CJ, Maki DG.The pathogenesis of ventilator-associaled pneu monia: its relevance to developing effective strategies far prevention. Respir Care. 2005;50:725-39; discussion 39-41. 55. Vincent JL, de Souza Barros D, Cianferoni S. Diagnosis, managemenl and pre vention of ventilator-associated pneumonia: an update. Drugs. 2010;70:1927-44. 56. Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israelí long-terrn care facility. Eur J Clin Microbio! Infecl Dis. 2005;24:17-22. 57. Wu Ul, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors far bloodstream infections due to extended-spectrum belalactamase-producing Escherichia coli. J Microbio! Immunol Jnfect. 2010;43:310-6. 58. Rodríguez-Baño J, Pican E, Gijon P, et al.Community-onset bacteremia due to extended-spectrum beta lactamase-producing Escherichia coli: risk factors and prognosis. Clin lnfect Dis. 2010;50:40-8. 59. Rodríguez-Baño J, Pican E, Gijon P, el al. Risk factors and prognosis of noso comial bloodstream infections caused by extended-spectrum-beta-lactamase producing Escherichia coli. J Clin Microbio). 2010;48:1726-31. 60. Rodríguez-Baño J, Navarro MD, Romero L, et al. Risk-factors far emerging bloodstream infeclions caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbio) Infect. 2008;14:180-3. 61. Chaiwarith R, Pasogpakdee P, Salee P, Kanjanaratanakorn K, Sirisanthana T, Supparatpinyo K. Risk factors far extended-spectrum beta lactamase-producing Klebsiella pneumoniae and Escherichia coli acquisition in a te11iary care teaching hospital in Thailand. J Hosp lnfect. England. 2009:285-6. 62. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan.J Hosp lnfect. 2003;53:39-45. 63. Kuster SP, Hasse B, Huebner V, et al.Risks factors far infections with extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care universityhospital in Switzerland. lnfection. 2010;38:33-40. 64. Kang CI, Song JH, Chung DR, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase producing Escherichia coli. lnt J Antimicrob Agents. 2010;36:284-7. 65. Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network far Study of Infectious D. Risk factors for infection and treatment outcome of exten ded-spectrum beta-lactamase-producing Eschericbia coli and Klebsiella pneu moniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91:I 15-21. 66. Hyle EP, Lipworth AD, Zaoutis TE, et al. Risk factors far increasing multidrug resistance among extended-spectrumbeta-lactamase-producing Escherichia coli and Klebsiella species. Clin lnfect Dis. 2005;40:1317-24. 67. Quirante OFn, Cerralo SG, Pardos SL. Risk factors for bloodstream infeclions caused by extended-spectrum 2-lactamase-producing Escherichia coli and Kleb siella pneumoniae. Braz J lnfect Dis. 2011 Jul-Aug;l5{4):370-6. 68. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Es cherichia coli producing exlended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J lnfect Dis. 2002;34:567-73. 69. Peña C, Gudiol C, Tubau F, et al. Risk-factors far acquisition of extended-spec trum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol lnfect. 2006;12:279-84. 70. García Hemandez A, García-Yazquez E, Gomez Gomez J, Canteras M, Her nandez-Torres A, Ruiz Gomez J. [Prediclive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients]. Med Clin (Barc). 2011;136:56-60. 71. Harris AD, McGregor JC, Johnson JA, et al. Risk faclors far colonization with extended-spectrum beta-lactarnase-producing bacteria and intensive care unit ad mission. Emerg lnfect Dis. 2007;13:1144-9. 72. Du B, Long Y. Liu H, el al. Extended-spectrum beta-lactamase-producing Es cherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med.2002;28:1718-23. 73. Wener KM, Schechner V, Gold HS, Wrighl SB, Carmeli Y. Trealment with fluoroquinolones or with beta-lactam-beta-laclamase inhibitor combinations is a risk factor far isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010;54:2010-6. 74. Velasco Arribas M, Barrena Puerta R, Asenjo Mota A, Yalverde Canovas JF, Delgado-lribarren A, Losa García JE. [Risk factors for extended espectrum bela lactamase producer E.coli bacteremia from urinary origin]. Med Clin (Barc). 2010;134:392-5.
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/843/876
dc.relation.citationedition.spa.fl_str_mv	Núm. 1 , Año 2013 : Enero – Marzo
dc.relation.citationendpage.none.fl_str_mv	20
dc.relation.citationissue.spa.fl_str_mv	1
dc.relation.citationstartpage.none.fl_str_mv	10
dc.relation.citationvolume.spa.fl_str_mv	22
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/843
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/d2d6ee7f-3ea3-44c5-9af7-f51067507fce/download
bitstream.checksum.fl_str_mv	bdea93bd96cae60802350e4929d22ae7
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1814355569545314304
spelling	Jiménez, Adriana40ca84fc8c49dba08c55b663e0d297a6500Carrero Forero, Germán4d71ebab1ca903098f90adc2f95ae0853002013-03-01 00:00:002022-06-29T19:37:16Z2013-03-012013-03-01 00:00:002022-06-29T19:37:16ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Saludhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/843factores de riesgoantibióticoresistenciabetalactamasas de espectro extendidorisk factorsantibioticresistanceextended-spectrum betalactamasesFactores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendidoRisk factors in extenoeo-spectrum betalactamase producing Escherichia coli ano Klebsiella pneumoniae infection and colonizationapplication/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/ARTREVhttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v22.n1.2013.8430121-7372https://repositorio.fucsalud.edu.co/handle/001/28622462-991Xhttps://doi.org/10.31260/RepertMedCir.v22.n1.2013.843spaVillegas MV, Kallan JN, Quinteros MG, Casellas JM. Prevalence of extended spectrum beta-Iactamases in South America. Clin Microbio! lnfect. 2008;14 Suppl 1:154-8. 2. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta Iactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50: 1257-62. 3. Paterson DL, Bonomo RA. Extended-spectrum beta-Iactamases: a clinical up date. Clin Microbio! Rev. 2005; 18:657-86. 4. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Anti microb Agents Chemother. 20 I 0;54:969-76. 5. Gunseren F, Marnikoglu L, Ozturk S, et al. A surveillance study of antimicrobial resistance of gram-negative bacteria isolated frorn intensive care units in eighl hospitals in Turkey. J Antimicrob Chemother. 1999;43:373-8. 6. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese !CU Study Groups. JAMA. 1999;281:67-71. 7. Albertini MT, Benoit C, Berardi L, et al. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended spectrurn beta-Iaclamase (ESBLE) in Northem France: a five-year multicentre incidence study. J Hosp Infect. 2002;52: 107-13. 8. Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME, Jiang H. Broad-spectrum, transmissible beta-lactamases. N Engl J Med. I 988;319:723-4. 9. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS. Occu rrence of newer beta-lactamáses in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother. 2002;46:3837-42. 10. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002;30:458-75. 11. Bell JM, Tumidge JD, Gales AC, Pfaller MA, Jones RN, Sentry ASG. Preva lence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbio! Infect Dis. 2002;42:193-8. 12. Lewis MT, Yamaguchi K, Biedenbach DJ, Jones RN. ln vitro evaluation of ce fepime and other broad-spectrum beta-lactams in 22 medica! centers in Japan: a phase II tria! comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn Microbio! lnfect Dis. 1999;35:307-15. 13. Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC, Jones RN. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicro bial agents tested against over 2,000 clinical isolates from 22 medica] centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn Microbio) Infect Dis. 1999;34:123-34. 14. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and charac terization of isolates from Europe, the Americas, and the Western Pacific region. Clin lnfect Dis. 2001;32 Suppl 2:S94-103. 15. Mendes C, Hsiung A, Kiffer C, et al. Evaluation of the in vitro activity of 9 antimicrobials against bacteria! strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program. Braz J lnfect Dis. 2000;4:236-44. 16. Miranda MC, Perez F, Zuluaga T, et al. [Antimicrobial resistance in gram nega tive bacteria isolated from intensive care units of Colombian hospitals, WHO NET 2003, 2004 and 2005]. Biomedica. 2006;26:424-33. 17. Otman J, Cavassin ED, Perugini ME, Vidotto MC. An outbreak of extended spectrum beta-lactamase-producing Klebsiella species in a neonatal intensive care unir in Brazil. lnfect Control Hosp Epidemiol. United States; 2002:8-9. 18. Pfaller MA, Jones RN, Doern GV. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resis tance Study Group. Diagn Microbiol lnfect Dis.1999;35:153-8. 19. Sader HS, Jones RN, Gales AC, et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medica! centers with a diag nosis of pneurnonia: analysis of results from the SENTRY Antimicrobial Surveil lance Program (] 997). SENTRY Latin America Study Group. Diagn Microbio! Infect Dis. 1998;32:289-301. 20. Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN, Group SS. Preva lence of antimicrobial resistance among respiratory tract isolates in Latin Amer ica: results from SENTRY antimicrobialsurveillance program (1997-98). Braz J Infect Dis. 2000;4:245-54. 21. Villegas MV, Correa A, Perez F, et al. Prevalence and characterization of ex tended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn Microbiol lnfect Dis. 2004;49:217-22. 22. Espinal P, Garza-Ramos U, Reyna F, et al. ldentification of SHV-type and CTX M-12 extended-spectrum beta-lactamases (ESBLs) in multiresistant Enterobac teriaceae from Colombian Caribbean hospitals. J Chemother. 2010;22:160-4. 23. Tumbarello M, Spanu T, Sanguinetti M, et al. llloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Che mother. 2006;50:498-504. 24. Superti SV, Augusti G, Zavascki AP. Risk factors for and mortality of exten ded-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escheri chia coli nosocornial bloodstream infections. Rev Inst Med Trop Sao Paulo. 2009;51:211-6. 25. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp lnfect. 2008;68:108-15. 26. Chenoweth CE, Saint S. Urinary tract infections. Infect Dis Clin North Am. 2011;25:103-15. 27. Saint S, Chenoweth CE. Biofilms and catheter-associated urinary tract infections. Infect Dis Clin North Am. 2003;17:411-32. 28. Warren JW, Darnron D, Tenney JH, Hoopes JM, Deforge B, Muncie HL, Jr. Fever, bacteremia, and death as complications of bacteriuria in women with long term urethral catheters. J Infect Dis. 1987;155:l 151-8. 29. Classen DC, Larsen RA, Burke JP, Stevens LE. Prevention of catheter associated bacteriuria: clinical tria] of methods to block three known pathways of infection. Am J lnfect Control. 1991;19:136-42. 30. Garibaldi RA, Burke JP, Britt MR, Miller MA, Smith CB. Meatal colonization and catheter-associated bacteriuria. N Engl J Med. l 980;303:316-8. 31. Hartstein Al, Garber SB, Ward TI, Jones SR, Morthland VH. Nosocomial uri nary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control. 1981;2:380-6. 32. Kunin CM, McCormack RC. Prevention of catheter-induced urinary-tract infec tions by sterile closed drainage. N Engl J Med. 1966;274:1155-61. 33. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary traer infection in adults: 2009 Internatio nal Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin lnfect Dis. 2010;50:625-63. 34. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg lnfect Dis. 2001;7:342-7. 35. Huth TS, Burke JP, Larsen RA, Classen DC, Stevens LE. Randomized tria! of meatal care with silver sulfadiazine cream for the prevention of catheter-associa ted bacteriuria. J Infect Dis. 1992;165:14-8. 36. Platt R, Polk BF, Murdock B, Rosner B. Risk factors for nosocomial urinary tract infection. Arn J Epidemiol. 1986;124:977-85. 37. Anderson DJ, Kirkland KB, Kaye KS, et al. Underresourced hospital infection control and prevention programs: penny wise, pound foolish? Infect Control Hosp Epidemiol. 2007;28:767-73. 38. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infec tions: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol. 1996;17:552-7. 39. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control. 2005;33:501-9. 40. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Net work (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control. 2008;36:609-26. 41. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgerson RB. An attachable silver-impregnated cuff for prevention of infection with cen_tral venous catheters: a prospective randomized multicenter trial. Am J Med. 1988:85:307-14. 42. Weber DJ, Rutala WA. Central line-associated bloodstream infections: preven tion and management. lnfect Dis Clin North Am. 2011;25:77-102. 43. Baker AM, Meredith JW, Haponik EF. Pneumonia in intubated trauma patients. Microbiology and outcomes. Am J Respir Crit Care Med. 1996;153:343-9. 44. Craig CP, Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Jnfect Control. 1984;12:233-8. 45. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA. Risk factors for nosocomial pneumonia: comparing adult critical-care popula tions. Am J Respir Crit Care Med. 1996;153:158-62. 46. Jourdain B, Novara A, Joly-Guillou ML, et al. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med. 1995;152:241-6. 47. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ven tilator-associated pneumonia among intensive care unit patients in a suburban medica) center. Crit Care Med.2003;31:1312-7. 48. Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL. Nosocomial pneumónia in Medicare patients. Hospital costs and reimbursement pattems under the prospec tive payment system. Arcb Jntern Med. 1991;151:1109-14. 49. van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ. Oral decontamination is cost-saving in the prevention of ventilator associated pneumonia in intensive care units. Crit Care Med. 2004;32:126-30. 50. Cook DJ, Walter SO, Cook RJ, et al. lncidence of and risk factors far ventilator associated pneumonia in critically ill patients. Ann Intem Med. l998;129:433- 40. 51. Stonecypher K. Yentilator-associated pneumonia: the importance of oral care in intubated adults. Crit Care Nurs Q. 2010;33:339-47. 52. Cmich CJ, Safdar N, Maki DG. The role of the intensive care unit environment in the pathogenesis and prevention of ventilator-associated pneumonia. Respir Care. 2005;50:813-36; discussion 36-8. 53. O'Keefe-McCarthy S.Evidence-based nursing strategies to prevenl ventilator acquired pneumonia. Dynamics. 2006;17:8-l l. 54. Safdar N, Cmich CJ, Maki DG.The pathogenesis of ventilator-associaled pneu monia: its relevance to developing effective strategies far prevention. Respir Care. 2005;50:725-39; discussion 39-41. 55. Vincent JL, de Souza Barros D, Cianferoni S. Diagnosis, managemenl and pre vention of ventilator-associated pneumonia: an update. Drugs. 2010;70:1927-44. 56. Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israelí long-terrn care facility. Eur J Clin Microbio! Infecl Dis. 2005;24:17-22. 57. Wu Ul, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors far bloodstream infections due to extended-spectrum belalactamase-producing Escherichia coli. J Microbio! Immunol Jnfect. 2010;43:310-6. 58. Rodríguez-Baño J, Pican E, Gijon P, et al.Community-onset bacteremia due to extended-spectrum beta lactamase-producing Escherichia coli: risk factors and prognosis. Clin lnfect Dis. 2010;50:40-8. 59. Rodríguez-Baño J, Pican E, Gijon P, el al. Risk factors and prognosis of noso comial bloodstream infections caused by extended-spectrum-beta-lactamase producing Escherichia coli. J Clin Microbio). 2010;48:1726-31. 60. Rodríguez-Baño J, Navarro MD, Romero L, et al. Risk-factors far emerging bloodstream infeclions caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbio) Infect. 2008;14:180-3. 61. Chaiwarith R, Pasogpakdee P, Salee P, Kanjanaratanakorn K, Sirisanthana T, Supparatpinyo K. Risk factors far extended-spectrum beta lactamase-producing Klebsiella pneumoniae and Escherichia coli acquisition in a te11iary care teaching hospital in Thailand. J Hosp lnfect. England. 2009:285-6. 62. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan.J Hosp lnfect. 2003;53:39-45. 63. Kuster SP, Hasse B, Huebner V, et al.Risks factors far infections with extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care universityhospital in Switzerland. lnfection. 2010;38:33-40. 64. Kang CI, Song JH, Chung DR, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase producing Escherichia coli. lnt J Antimicrob Agents. 2010;36:284-7. 65. Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network far Study of Infectious D. Risk factors for infection and treatment outcome of exten ded-spectrum beta-lactamase-producing Eschericbia coli and Klebsiella pneu moniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91:I 15-21. 66. Hyle EP, Lipworth AD, Zaoutis TE, et al. Risk factors far increasing multidrug resistance among extended-spectrumbeta-lactamase-producing Escherichia coli and Klebsiella species. Clin lnfect Dis. 2005;40:1317-24. 67. Quirante OFn, Cerralo SG, Pardos SL. Risk factors for bloodstream infeclions caused by extended-spectrum 2-lactamase-producing Escherichia coli and Kleb siella pneumoniae. Braz J lnfect Dis. 2011 Jul-Aug;l5{4):370-6. 68. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Es cherichia coli producing exlended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J lnfect Dis. 2002;34:567-73. 69. Peña C, Gudiol C, Tubau F, et al. Risk-factors far acquisition of extended-spec trum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol lnfect. 2006;12:279-84. 70. García Hemandez A, García-Yazquez E, Gomez Gomez J, Canteras M, Her nandez-Torres A, Ruiz Gomez J. [Prediclive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients]. Med Clin (Barc). 2011;136:56-60. 71. Harris AD, McGregor JC, Johnson JA, et al. Risk faclors far colonization with extended-spectrum beta-lactarnase-producing bacteria and intensive care unit ad mission. Emerg lnfect Dis. 2007;13:1144-9. 72. Du B, Long Y. Liu H, el al. Extended-spectrum beta-lactamase-producing Es cherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med.2002;28:1718-23. 73. Wener KM, Schechner V, Gold HS, Wrighl SB, Carmeli Y. Trealment with fluoroquinolones or with beta-lactam-beta-laclamase inhibitor combinations is a risk factor far isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010;54:2010-6. 74. Velasco Arribas M, Barrena Puerta R, Asenjo Mota A, Yalverde Canovas JF, Delgado-lribarren A, Losa García JE. [Risk factors for extended espectrum bela lactamase producer E.coli bacteremia from urinary origin]. Med Clin (Barc). 2010;134:392-5.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/843/876Núm. 1 , Año 2013 : Enero – Marzo2011022Revista Repertorio de Medicina y Cirugíainfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2PublicationOREORE.xmltext/xml2805https://repositorio.fucsalud.edu.co/bitstreams/d2d6ee7f-3ea3-44c5-9af7-f51067507fce/downloadbdea93bd96cae60802350e4929d22ae7MD51001/2862oai:repositorio.fucsalud.edu.co:001/28622024-02-02 13:11:44.042https://creativecommons.org/licenses/by-nc-sa/4.0/metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Factores de riesgo en infección y colonización por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido

Publicaciones similares